Enrico Martin

132 Chapter 6 19. Spurlock G, Knight SJL, Thomas N, et al. Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings. J Cancer Res Clin Oncol . 2010;136:1869–1880. 20. Benz MR, Czernin J, Dry SM, et al. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer . 2010;116:451–458. 21. Ahlawat S, Blakeley JO, Rodriguez FJ, et al. Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Neurology . 2019;93:e1076–e1084. 22. Broski SM, Johnson GB, Howe BM, et al. Evaluation of 18F-FDG PET and MRI in differentiating benign and malignant peripheral nerve sheath tumors. Skeletal Radiol . 2016;45:1097–1105. 23. Frankel S, Smith GD, Donovan J, et al. Screening for prostate cancer. Lancet (London, England) . 2003;361:1122–1128. 24. Sauter ER. Reliable Biomarkers to Identify New and Recurrent Cancer. Eur J breast Heal . 2017;13:162–167. 25. Chu GCW, Lazare K, Sullivan F. Serum and blood based biomarkers for lung cancer screening: a systematic review. BMC Cancer . 2018;18:181. 26. Guo J, Riebler A, Rue H. Bayesian bivariate meta-analysis of diagnostic test studies with interpretable priors. Stat Med . 2017;36:3039–3058. 27. Simpson D, Rue H, Riebler A, et al. Penalising Model Component Complexity: A Principled, Practical Approach to Constructing Priors. Stat Sci . 2017;32:1–28. 28. EUnetHTA. Meta-analysis of Diagnostic Test Accuracy Guideline. 2014;1–45. 29. Ahlawat S, Fayad LM. Imaging cellularity in benign and malignant peripheral nerve sheath tumors: Utility of the “target sign” by diffusion weighted imaging. Eur J Radiol . 2018;102:195–201. 30. Chhabra A, Soldatos T, Durand DJ, et al. The role of magnetic resonance imaging in the diagnostic evaluation of malignant peripheral nerve sheath tumors. Indian J Cancer . 2011;48:328–334. 31. Demehri S, Belzberg A, Blakeley J, et al. Conventional and functional MR imaging of peripheral nerve sheath tumors: Initial experience. Am J Neuroradiol . 2014;35:1615–1620. 32. Derlin T, Tornquist K, Münster S, et al. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med . 2013;38:e19–e25. 33. Karsy M, Guan J, Ravindra VM, et al. Diagnostic Quality of Magnetic Resonance Imaging Interpretation for Peripheral Nerve Sheath Tumors: Can Malignancy Be Determined? J Neurol Surgery, Part A Cent Eur Neurosurg . 2016;77:495–504. 34. Li CS, Huang GS, Wu HD, et al. Differentiation of soft tissue benign and malignant peripheral nerve sheath tumors with magnetic resonance imaging. Clin Imaging . 2008;32:121–127. 35. Matsumine A, Kusuzaki K, Nakamura T, et al. Differentiation between neurofibromas and malignant peripheral ner ve sheath tumors in neurofibromatosis 1 evaluated by MRI. J Cancer Res Clin Oncol . 2009;135:891–900. 36. Matsumoto Y, Endo M, Harimaya K, et al. Malignant peripheral nerve sheath tumors presenting as spinal dumbbell tumors: clinical outcomes and characteristic imaging features. Eur Spine J . 2015;24:2119–2125. 37. Schwabe M, Spiridonov S, Yanik EL, et al. How Effective Are Noninvasive Tests for Diagnosing Malignant Peripheral Nerve Sheath Tumors in Patients with Neurofibromatosis Type 1? Diagnosing MPNST in NF1 Patients. Sarcoma . 2019;2019:4627521.